Imiglitazar NEW

Price	$700	$1800
Package	1mg	5mg

Supply Ability:	10g
Update Time:	2026-04-21

Product Details

Product Name: Imiglitazar	CAS No.: 250601-04-8
Purity: 97.33%	Supply Ability: 10g
Release date: 2026/04/21

Product Introduction

Bioactivity

Name	Imiglitazar
Description	Imiglitazar (TAK559) is a potent PPAR-β/δ receptor agonist with hypoglycemic effects.
In vitro	TAK-559, a partial agonist for hPPARg1, achieves approximately 68% of the maximal activation obtained with rosiglitazone, a known PPARγ agonist. Significant activation of PPARγ is observed at a high concentration (10 μM) of TAK-559. Competition-binding assays using radiolabeled ligand indicate that the transactivation of all hPPAR subtypes by TAK-559 is a result of direct binding of TAK-559 to each subtype. TAK-559 also recruits the coactivator SRC-1 to both hPPARγ1 and hPPARα, and dissociates the corepressor NCoR from both hPPARγ1 and hPPARα[1]. In the presence of 10 μM TAK-559, TNFα- or IL-1β-induced THP-1 cell attachment to cultured endothelial cells is significantly reduced. The secretion of monocyte chemoattractant protein-1 (MCP-1) from endothelial cells is reduced by 36%, accompanied by decreased mRNA expression in the cells. Furthermore, the proliferation and migration of cultured smooth muscle cells are significantly decreased in the presence of TAK-559[3].
In vivo	During TAK-559 treatment, significant elevation of circulating high-density lipoprotein (HDL) cholesterol levels is observed, characterized by an increase in large HDL particles and a decrease in small dense HDL particles. Concurrently, plasma triglyceride and apolipoprotein B-100 levels decrease, while apolipoprotein A-I increases. Hyperinsulinemia and insulin resistance are significantly corrected with the highest dose of 3.0 mg/kg per day in these prediabetic monkeys. Additionally, no adverse effects on representative liver function parameters are observed during the study period[2].
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Keywords	TAK559 \| TAK 559 \| PPARδ \| PPARγ1 \| PPARβ \| PPARα \| Imiglitazar
Inhibitors Related	PHYTOL \| Rosiglitazone \| Retinoic acid \| Daidzein \| Fenofibrate \| Magnesium acetate tetrahydrate \| Maltitol \| Naringenin \| 2,3-Butanediol \| NPC 15199 \| Icariin \| Cloxiquine

Company Profile Introduction

TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds. 170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.